Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Maria P. Civeira"'
Autor:
Jose-I. Riezu-Boj, Maria P. Civeira, Iosu Sola, Laura Guembe, Jesús Prieto, Rafael Aldabe, Esther Larrea, Pablo Sarobe, Itziar Echeverria
Publikováno v:
Journal of Hepatology. 60:482-489
Background & Aims Oncostatin M (OSM) is an inflammatory cytokine which interacts with a heterodimeric receptor formed by gp130 and either OSMRβ or LIFR. Here we have analysed OSM and its receptors in livers with chronic hepatitis C (CHC) and studied
Autor:
Juan José Lasarte, Rafael Aldabe, Esther Larrea, Noelia Casares, Jose I Riezu-Boj, Babs E. Verstrepen, Takaji Wakita, Maria P. Civeira, Jesús Prieto, Christine S. Rollier, Jonathan L. Heeney, Pablo Sarobe, Francisco Borrás-Cuesta, Lucía Gil-Guerrero
Indoleamine 2,3-dioxygenase (IDO) is induced by proinflammatory cytokines and by CTLA-4-expressing T cells and constitutes an important mediator of peripheral immune tolerance. In chronic hepatitis C, we found upregulation of IDO expression in the li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4768a62f13b08e91a6badfc6c9b3a34
https://doi.org/10.1128/jvi.02248-06
https://doi.org/10.1128/jvi.02248-06
Autor:
Enrique De Alava, Félix Contreras, Marta García-Granero, Jesús J. Vázquez, J. Camps, Maria P. Civeira, Jesús Prieto, Javier Pardo-Mindán, Miguel Angelo Munoz, Jesús J. Sola, A. Castilla
Publikováno v:
Europe PubMed Central
To assess the effect of long-term alfa interferon therapy (12 months) on liver histology of chronic hepatitis C, we studied 61 treated patients, and compared their outcome with 28 untreated cases followed as controls. A liver biopsy was taken from al
Publikováno v:
Antiviral Research. 76:194-197
Hepatitis C virus (HCV) is remarkably efficient at establishing persistent infection. The current treatment with IFN-alpha given alone or in combination with ribavirin is ineffective in eliminating the virus in a large proportion of individuals with
Autor:
J. Ignacio Herrero, Nicolás García, Bruno Sangro, Andrés Peña, Jorge Quiroga, Iosu Sola, Jesús Prieto, Maria P. Civeira, Javier A. Cienfuegos
Publikováno v:
Liver Transplantation and Surgery. 4:265-270
Recurrent hepatitis C is a frequent complication after liver transplantation for hepatitis C virus-related cirrhosis, but risk factors related to its development remain ill defined. Twenty-three patients receiving a primary liver graft for hepatitis
Autor:
J. Guillen, Jose I Riezu-Boj, Jie-Han Su, Juan José Lasarte, Jesús Prieto, Zhi-Chun Xie, Maria P. Civeira
Publikováno v:
Virology. 244:513-520
Although hepatitis C virus (HCV) infection can be reproduced in chimpanzees, these animals are rare and expensive. Tree shrews (tupaias) are small animals, closely related to primates, which adapt easily to a laboratory environment. In this work we h
Autor:
Itziar Echeverria, Anangi Balasiddaiah, Pablo Sarobe, Jose-I. Riezu-Boj, Pablo Gastaminza, Laura Guembe, Jesús Prieto, Maria P. Civeira, Esther Larrea, Rafael Aldabe
Publikováno v:
Gut. 63(4)
Background IL-7 and IL-15 are produced by hepatocytes and are critical for the expansion and function of CD8 T cells. IL-15 needs to be presented by IL-15Rα for efficient stimulation of CD8 T cells. Methods We analysed the hepatic levels of IL-7, IL
Autor:
Maria P. Civeira, Isidro Prieto, Juan José Lasarte, Jesús Prieto, José Golvano, Arturo Gullón, Pablo Sarobe, Francisco Borrás-Cuesta
Publikováno v:
AIDS Research and Human Retroviruses. 12:1023-1030
Phenylalanine-containing peptides from CD4 were synthesized on the basis of chemical similarity with active CD4(81-92)-benzylated peptides. Systematic replacement of amino acids of these peptides bearing the benzyl group by phenylalanine, afforded se
Autor:
Maria P. Civeira, J. Camps, Enrique de Alava, A. Castilla, Marta García-Granero, Jesús Prieto, Esther Larrea, Jose I Riezu-Boj
Publikováno v:
Dadun. Depósito Académico Digital de la Universidad de Navarra
instname
instname
alpha-Interferon therapy normalizes aminotransferase levels in approximately 50% of the patients with chronic hepatitis C, but post-therapy relapses are common and predictive factors of sustained response remain largely unknown. We retrospectively as
Publikováno v:
Journal of Hepatology. 17:390-396
Seventy-two patients with chronic hepatitis C were included in a randomised trial of lymphoblastoid interferon versus no treatment. Thirty-six patients entered each group. Interferon was given in a step-down schedule for 12 months. Aminotransferase a